Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Rovalpituzumab

1

V.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

1
Last update : 11/07/2021
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist

Publications

A Phase 1 Study Evaluating Rovalpituzumab Tesirine in Frontline Treatment of Patients With Extensive-Stage SCLC.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2021 Sep;16;1582-1588 2021 Sep
A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2021 Sep;16;1559-1569 2021 Sep
Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU Study.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2021 Sep;16;1570-1581 2021 Sep
Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2019 Sep;135;145-150 2019 Sep
Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Dec 01;25;6958-6966 2019 Dec 01
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.
The Lancet. Oncology 2017 Jan;18;42-51 2017 Jan

Powered by

  • ^
  • Contact
  • Cookies
  • About